scholarly article | Q13442814 |
P356 | DOI | 10.1089/THY.2013.0240 |
P8608 | Fatcat ID | release_ptbfk3rbhndm7e6nxg2yf2kuua |
P932 | PMC publication ID | 3887427 |
P698 | PubMed publication ID | 23980907 |
P50 | author | Francesco Latrofa | Q41657299 |
Marco Nardi | Q57628989 | ||
Maria Antonietta Profilo | Q61054438 | ||
P2093 | author name string | Claudio Marcocci | |
Francesca Menconi | |||
Paolo Vitti | |||
Michele Marinò | |||
Roberto Rocchi | |||
Marenza Leo | |||
Eleonora Sisti | |||
Maria Antonietta Altea | |||
P2860 | cites work | Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids | Q79771160 |
Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy | Q82104621 | ||
Selenium and the course of mild Graves' orbitopathy | Q28238021 | ||
Graves' ophthalmopathy | Q28274196 | ||
Management of Graves' ophthalmopathy: reality and perspectives | Q33899550 | ||
Natural history of thyroid associated ophthalmopathy | Q34059445 | ||
Rundle and his curve | Q34170719 | ||
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens | Q35215882 | ||
Immunosuppressive treatment of Graves' ophthalmopathy | Q35469963 | ||
Graves' ophthalmopathy: state of the art and perspectives | Q35785171 | ||
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy | Q37110191 | ||
Clinical practice. Graves' ophthalmopathy | Q37407540 | ||
Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. | Q37751763 | ||
Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy | Q38013216 | ||
Thyroid volume and severity of Graves' orbitopathy | Q43745434 | ||
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism | Q43907362 | ||
A treatment strategy for Graves' orbitopathy | Q44252754 | ||
Natural history of thyroid eye disease | Q47759032 | ||
Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. | Q48560620 | ||
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 | ||
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. | Q51258119 | ||
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism | Q57482592 | ||
Modification of the Classification of the Eye Changes of Graves' Disease: Recommendations of the Ad Hoc Committee of The American Thyroid Association | Q67020629 | ||
Ophthalmic Graves's disease: natural history and detailed thyroid function studies | Q67020768 | ||
Prevalence, natural history and surgical treatment of exophthalmos | Q69395891 | ||
Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? | Q72414211 | ||
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy | Q74010201 | ||
Management of exophthalmos and related ocular changes in Graves' disease | Q74338185 | ||
Graves' ophthalmopathy: natural history and treatment outcomes | Q77575202 | ||
P433 | issue | 1 | |
P304 | page(s) | 60-66 | |
P577 | publication date | 2013-12-09 | |
P1433 | published in | Thyroid | Q15709940 |
P1476 | title | Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited | |
P478 | volume | 24 |
Q53192241 | Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment? |
Q38784922 | Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy. |
Q91842643 | Analysis of Foveal and Parafoveal Microvascular Density and Retinal Vessel Caliber Alteration in Inactive Graves' Ophthalmopathy |
Q89680367 | Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) |
Q52715564 | Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. |
Q101166513 | Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases |
Q42667849 | Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question |
Q26782424 | Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management |
Q89868242 | Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy |
Q86549348 | Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy |
Q37616156 | Methotrexate for the treatment of thyroid eye disease |
Q38963406 | Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease? |
Q48318128 | Natural history of graves' orbitopathy after treatment. |
Q64248548 | Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up |
Q35055124 | Randomized controlled trial of rituximab in patients with Graves' orbitopathy |
Q26749195 | THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy |
Q55140443 | Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future. |
Q38367695 | Total thyroid ablation in Graves' orbitopathy |
Search more.